Influence of food intake on the pharmacokinetics of avosentan in man

International Journal of Clinical Pharmacology and Therapeutics

Volumn 46, Issue 9, 2008, Pages 453-458

  Dieterle, W ^a   Hengelage, T ^b  

^a Drug Disposition Consultants   (Germany)

^b Speedel Pharma AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYMETHYLPYRIDINE 2 SULFONIC ACID[6 METHOXY 5 (2 PHENOXY) 2 (PYRIDIN 4 YL)PYRIMIDIN 4 YL]AMIDE; AVOSENTAN; DRUG METABOLITE; RO 68 5925; UNCLASSIFIED DRUG;

ABNORMAL LABORATORY RESULT; ADULT; AREA UNDER THE CURVE; ARTICLE; ATTENTION DISTURBANCE; CALORIC INTAKE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CROSSOVER PROCEDURE; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG METABOLISM; DRUG TOLERABILITY; EDEMA; ELECTROCARDIOGRAM; FATIGUE; FEMALE; FOOD; FOOD DRUG INTERACTION; FOOD INTAKE; HUMAN; HUMAN EXPERIMENT; LIPID DIET; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NORMAL HUMAN; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SYSTOLIC BLOOD PRESSURE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 52149115147     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP46453     Document Type: Article

References (10)

1. Data on file. Basel, Switzerland: Speedel Pharma Ltd.
2. A-selective endothelin receptor antagonist SPP301 in healthy human subjects. J Clin Pharmacol. 2004; 44: 59-66.
3. A endothelin-receptor antagonist SPP301 in man. Int J Clin Pharmacol Ther. 2005; 43: 178-186.
4. Gibaldi M, Perrier D. Pharmacokinetics. 2nd ed. New York: Marcel Dekker; 1982.
5. Lausecker B, Fischer G. Development of a liquid chromatographic/ tandem mass spectrometric assay for a new endothelin receptor antagonist, and its application to dog plasma samples generated after simultaneous i.v. and p.o. administration of the unlabeled and deuterium-labeled forms of this antagonist. J Mass Spectrom. 2003; 38: 649-658.
6. Lüscher TF, Barton M. Endothelin and endothelin receptor antagonists: therapeutic considerations for a novel class of cardiovascular drugs. Circulation. 2000; 102: 2434-2400.
7. Singh BN. Effects of food on clinical pharmacokinetics. Clin Pharmacokinet. 1999; 37: 213-255.
8. Steinijans VW, Hartmann M, Huber R, Radtke HW. Lack of pharmacokinetic interaction as an equivalence problem. Int J Clin Pharmacol Ther Toxicol. 1991; 29: 323-328.
9. A-selective antagonist SPP301 on top of standard treatment reduces urinary albumin excretion rate in patients with diabetic nephropathy. Abstract presented at: 38th American Society of Nephrology Renal Week; Philadelphia; November 8-13, 2005. Abstract 550471.
10. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature. 1988; 332: 411-415.